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May 7, 2013:1929–34confidence interval: 1.04 to 1.22) despite of reducing the risk of
cardiovascular events by 0.84 (95% confidence interval: 0.75 to
0.94), compared with moderate-dose statins (3). I speculate that
long-term adverse effects of NOD may generate a relative
increase in deaths. Indeed, a recent large-scale randomized
clinical trial confirms my speculation. In individuals with 1 or
more risk factors for diabetes, statin was associated with a 39%
reduction in the primary endpoint, but in individuals with no
major diabetes risk factors, statin was associated with a 52%
reduction in the primary endpoint (4). One should consider that
higher dose statin therapy may cause more adverse effects and
therefore lead to differences in routine clinical care between
those treated with higher and lower dose regimens. Thus, it is
important to consider the cardiovascular and metabolic context
and natural history of diseases when choosing statin therapy for
optimal individual patient health over the long term (5).
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Statin Treatment and Diabetes
Waters et al. (1) discuss further evidence relating to increased
incidence of new diabetes with statins. Superficially, the message from
these and other studies is reassuring: statins have transformed the
management of atherosclerotic disease; intensive therapy shows
greater benefit than “standard” therapy; the rate of incident diabetes
with statins is relatively small; benefits of statins are still apparent in
patients with diabetes. It is further reassuring from this study (using data
from the TNT [Treating to New Targets] and IDEAL [Incremental
Decrease in Endpoints through Aggressive Lipid-lowering] studies) that
those who develop diabetes are those who appear to be at risk.
The authors imply, but do not state, that all 4 risk factors for
diabetes considered were equally important, and that there was nodifference in incident diabetes between those with no or 1 risk factor.
It is surprising that age was not considered as a factor in their analysis.
Recent analyses of data from major lipid trials have documented the
incidence of diabetes based on fasting glucose, but postprandial data
are not available. The rate of incident diabetes may thus be underes-
timated. The effect of statins on diabetes incidence may also be
underestimated because many of the patients in lipid trials have
already been exposed to statins prior to the trial. Also, the comparators
in the TNT and IDEAL studies (10 mg atorvastatin or 20 mg
simvastatin) may themselves increase incident diabetes, thus partially
masking the influence of intensive therapy.
It is unlikely that statins cause diabetes, but rather exacerbate a
pre-existing dysglycemic state. Their impact almost certainly goes
beyond the reported annual 2% increase in new diabetes. In the
TNT and IDEAL studies, around 17% of patients had diabetes at
baseline (previously diagnosed or increased fasting plasma glucose
[FPG]). Deterioration in glycemic control in diabetic patients
using statins is well documented (2) but has not been as extensively
studied as the increase in incident diabetes. The increase in HbA1c
with statins is similar in magnitude to the decrease seen with the
newer classes of oral hypoglycemic agents. The mechanism is not
known. Impaired -cell function may well be involved (2), but
mpaired insulin sensitivity has also been documented (3). If
mpaired insulin secretion is the predominant mechanism, then
ncreased FPG may be the earliest diagnostic criterion for diabetes
o be satisfied. If the problem is impaired insulin sensitivity, then
ncreased postprandial glucose may appear first. Postprandial
nsulin and lipid excursions are well known to contribute to
rogression of macrovascular disease.
Development of diabetes or worsening of its control has the
otential to impair quality of life through increased need for
reatment, increased clinic visits, side effects of treatment, and
evelopment of complications. These considerations are not minor
ut we should certainly not deny patients the considerable benefits
f statins where they are indicated. Statins can be lifesaving, but it
s noteworthy that intensive statin therapy was not associated with
ecreased overall or cardiovascular mortality in either the TNT or
DEAL studies. Careful consideration of the risks and benefits are
eeded in each case, and we need greater understanding of the
iffering effects of class members on glucose homeostasis.
Richard L. Kennedy, MD, PhD
enkat Vangaveti, MSc, PhD
sman H. Malabu, MBBS
School of Medicine
eakin University
aurn Ponds Campus
eelong, Victoria 3220
ustralia
-mail: lee.kennedy@deakin.edu.au
http://dx.doi.org/10.1016/j.jacc.2013.01.071
EFERENCES
1. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event
reduction versus new-onset diabetes during atorvastatin therapy: effect
of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148–52.
2. Bellia A, Rizza S, Lombardo MF, et al. Deterioration of glucose
homeostasis in type 2 diabetic patients one year after beginning statins
therapy. Atherosclerosis 2012;223:197–203.
b
d
d
r
a
p
m
g
n
C
2
t
(
g
A
D
w
a
c
(
H
I
L
i
o
T
d
b
(
m
o
r
a
t
t
a
c
C
f
R
1934 Correspondence JACC Vol. 61, No. 18, 2013
May 7, 2013:1929–343. Baker WL, Talati R, White MC, Coleman CI. Differing effects of statins
on insulin sensitivity in non-diabetics: a systematic review and meta-
analysis. Diabetes Research and Clinical Practice 2010;87:98–107.
Reply
We thank Dr. Kennedy and colleagues and Dr. Koh for their
interest in our paper (1). In response to Dr. Kennedy, we
previously compared the strengths of the 4 major risk factors for
diabetes across 3 large statin trials (2). Fasting blood sugar is the
strongest predictor, which is not a surprise because it is used for the
diagnosis of diabetes. Age was considered, but was not a predictor
of diabetes in any of these 3 trials (2).
We agree with Dr. Kennedy that the incidence of diabetes may
e underestimated in these trials. Unfortunately, the risk of
iabetes with statins was not recognized when these trials were
esigned and executed. Thus, endpoint ascertainment is highly
eliable for cardiovascular events, but less so for diabetes. Meta-
nalyses clearly show a stepwise increase in incident diabetes from
lacebo to low-dose to high-dose statin therapy, with the incre-
ents being 9% and 16%, respectively (3,4).
Data from clinical trials indicate that the deterioration in
lycemic control related to statins in patients with diabetes may
ot be as large as that suggested by Dr. Kennedy and colleagues. In
ARDS (Collaborative Atorvastatin Diabetes Study), where
,838 patients with type 2 diabetes were randomized to atorvasta-
in 10 mg/day or placebo and followed for a median of 3.9 years
5), the adjusted mean difference in HbA1C between the treatment
roups at the end of the study was only 0.105% (p  0.03). In the
SPEN (Atorvastatin Study for Prevention of Coronary Heart
isease Endpoints in Non-insulin-dependent Diabetes) study,
here 2,410 patients with type 2 diabetes were randomized to
torvastatin 10 mg/day or placebo and followed for 4 years, the
hanges in HbA1C were identical, 0.2%, in the 2 treatment groups
6). A random sample of 1,087 participants with diabetes in the
eart Protection Study had HbA1C measurements at baseline and
after an average of 4.6 years of follow-up. The increase in HbA1C
was slightly but not statistically significantly higher in the simva-
statin 40 mg group compared to placebo (7).
Neither the TNT (Treating to New Targets) study nor the
DEAL (Incremental Decrease in End points through Aggressive
ipid lowering) study was powered to show a significant decrease
n overall or cardiovascular mortality. Indeed, in the meta-analysis
f more versus less intensive statin therapy (which included the
NT and IDEAL studies), the overall incidence of coronary heart
isease (CHD) death was only 0.7% (8). Nevertheless, the com-
ined endpoint of CHD death or nonfatal MI was reduced
relative risk: 0.71; 95% confidence interval: 0.58 to 0.87 per 1
mol/l reduction in low-density lipoprotein cholesterol), as were
ther important endpoints such as ischemic stroke and coronary
evascularization. The benefits of more intensive statin therapy
re clearly established.
We disagree with Dr. Koh’s conclusion that “higher dose statin
herapy does not have any benefit compared with lower dose statin
herapy,” both for the reason described in the preceding paragraph,
nd because the impact of new onset diabetes is relatively minor
ompared to the cardiovascular events included in our analysis:
HD death, myocardial infarction, resuscitated cardiac arrest, and
atal or nonfatal stroke. Comparing one hazard ratio to another ismisleading because the types of events are not equivalent. As noted
in our paper, nearly 20% of patients with an event had more than
one of them, and other cardiovascular events that are prevented by
statin treatment such as coronary revascularization, new onset
angina, and transient ischemic attack were not included in our
analysis.
Dr. Koh speculates that the long-term adverse effects of new
onset diabetes with statins might generate a relative increase in
deaths, and cites data from the JUPITER (Justification for the Use
of statins in Prevention: an Intervention Trial Using Rosuvastatin)
trial as support. The median follow-up of JUPITER trial patients
was only 1.9 years, and despite a significant increase in incident
diabetes in the rosuvastatin treatment group, all major cardiovas-
cular events were reduced by nearly half. Even among the patients
who did develop diabetes during the trial, rosuvastatin was asso-
ciated with a risk reduction similar to that seen in the overall group
(9). We agree with the conclusion of that report, that “the
cardiovascular and mortality benefits of statin therapy exceed the
diabetes hazard, including in participants at high risk of developing
diabetes.”
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